文献类型：期刊文献

中文题名：芪苈强心胶囊联合左西孟旦治疗慢性心力衰竭的系统评价和试验序贯分析

英文题名：Systematic Review and Sequential Analysis of the Combination of Qili Qiangxin Capsules and Levosimendan for the Treatment of Chronic Heart Failure

作者：陈亚婷[1];张丽[2];蒋虎刚[1,2];王新强[2];任春贞[1];刘凯[3];李应东[1,2];赵信科[1,2]

第一作者：陈亚婷

机构：[1]甘肃中医药大学,甘肃兰州730000;[2]甘肃中医药大学附属医院,甘肃兰州730020;[3]甘肃医学院附属医院,甘肃平凉744000

第一机构：甘肃中医药大学

年份：2025

卷号：37

期号：12

起止页码：2459

中文期刊名：中医药临床杂志

外文期刊名：Clinical Journal of Traditional Chinese Medicine

基金：中医药传承与创新“百千万”人才工程(岐黄工程)青年岐黄学者基金资助项目;国家中医药管理局“李应东全国名中医传承工作室”建设项目(国中医药办人教函〔2022〕5号);甘肃省科技重大专项计划(20ZD7FA002);甘肃省中医药科研课题项目(GZKZD-2018-02,GZKP-2023-59)。

语种：中文

中文关键词：慢性心力衰竭;芪苈强心胶囊;左西孟旦;随机对照试验;系统评价;序贯分析

外文关键词：Chronic heart failure;Qili Qiangxin Capsules;Levosimendan;Randomized controlled trial;Systematic review;Sequential analysis

摘要：目的:采用系统评价的方法,研究芪苈强心胶囊与左西孟旦联合治疗慢性心衰(CHF)的有效性和安全性。方法:系统检索BMJ Best Practice、Up To Date、GIN、NICE、Cochrane library、Embase、PubMed、Web of science、CBM、CNKI、万方、维普及美国心脏病协会关于芪苈强心胶囊与左西孟旦协同治疗CHF的随机对照试验(RCT),检索时间从建立数据库开始,截至2024年8月15日。由2名研究者分别进行文献遴选、数据提炼及偏倚风险评估。采取Stata18和Revman5.4分析数据,采用TSA0.9.5.10软件进行序贯分析。结果:纳入14篇RCTs,包括1389例患者,其中试验组695例(芪苈强心胶囊联合左西孟旦),对照组694例(左西孟旦)。Meta结果显示:芪苈强心胶囊联合左西孟旦可提高治疗有效率[RR=1.2,95%CI(1.14,1.26),P<0.01],增加6min步行距离[MD=41.71,95%CI(19.68,63.74),P<0.01],降低N末端脑利钠肽前体水平(NT-pro BNP)[MD=-466.34,95%CI(-733.15,-199.533),P<0.01],提高左心室射血分数(LVEF)[MD=7.99,95%CI(4.10,11.88),P<0.01],增加每搏输出量[MD=10.97,95%CI(6.27,15.66),P<0.01],TSA进一步表明:芪苈强心胶囊联合左西孟旦治疗慢性心衰有效率结论的可靠性。结论:芪苈强心胶囊联合左西孟旦治疗CHF的疗效优于单用左西孟旦,对于改善CHF患者的心功能是积极有效的。
Objective:To investigate the efficacy and safety of Qili Qiangxin Capsules combined with levosimendan in the treatment of chronic heart failure(CHF)using a systematic review method.Methods:Randomized controlled trials(RCTs)of Qili Qiangxin Capsules combined with levosimendan for the treatment of CHF were systematically searched in BMJ Best Practice,Up To Date,GIN,NICE,Cochrane Library,Embase,PubMed,Web of Science,CBM,CNKI,Wanfang,VIP,and the American Heart Association database.The search period was from the database inception to August 15,2024.Two researchers were responsible for literature selection,data extraction,and risk of bias assessment.Stata 18 and Revman 5.4 were used for data analysis,and TSA 0.9.5.10 software was used for sequential analysis.Results:14 RCTs were included,involving 1389 patients,of whom 695 were in the experimental group(Qili Qiangxin Capsules combined with Levosimendan)and 694 were in the control group(Levosimendan).Meta-analysis results showed that the combination of Qili Qiangxin Capsules and levosimendan improved the therapeutic efficacy[RR=1.2,95%CI(1.14,1.26),P<0.01],increased 6-minute walking distance(6MWT)[MD=41.71,95%CI(19.68,63.74),P<0.01],decreased N-terminal pro-brain natriuretic peptide(NT-proBNP)levels[MD=-466.34,95%CI(-733.15,-199.533),P<0.01],increased left ventricular ejection fraction(LVEF)[MD=7.99,95%CI(4.10,11.88),P<0.01],and increased stroke volume[MD=10.97,].[95%CI(6.27,15.66),P<0.01],TSA further confirms the reliability of the conclusion regarding the efficacy of Qili Qiangxin Capsules combined with levosimendan in treating chronic heart failure.Conclusion:The efficacy of Qili Qiangxin Capsules combined with levosimendan in treating CHF is superior to levosimendan alone,and it is positive and effective in improving cardiac function in CHF patients.